Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
University of Kentucky Pfizer |
---|---|
Information provided by: | University of Kentucky |
ClinicalTrials.gov Identifier: | NCT00754273 |
To determine the prevalence of MRSA isolates with marginal susceptibility to vancomycin or heteroresistance.
Condition | Intervention |
---|---|
MRSA Pneumonia |
Other: etest susceptability testing |
Study Type: | Observational |
Study Design: | Case-Only, Prospective |
Official Title: | Prospective Evaluation Of Protected Alveolar Lavage (PAL) Staphylococcus Aurues Resistance Patterns |
Estimated Enrollment: | 1250 |
Study Start Date: | September 2008 |
Estimated Study Completion Date: | September 2009 |
Estimated Primary Completion Date: | July 2009 (Final data collection date for primary outcome measure) |
Groups/Cohorts | Assigned Interventions |
---|---|
1
PAL samples collected for pneumonia evaluation
|
Other: etest susceptability testing
E-test methodology is performed on all MRSA samples using standardized inoculum (0.5 McFarland) for Tigecycline, Vancomycin, Teicoplanin, and Linezolid. E test is performed using heavy inoculum for Vancomycin and Teicoplanin (2.0 McFarland).
|
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
One hundred consecutive isolates of MRSA will be analyzed.
Inclusion Criteria:
Exclusion Criteria:
Contact: Andrew C Bernard | 859-323-6346 | acbern00@uky.edu |
United States, Kentucky | |
University of Kentucky Medical Center | |
Lexington, Kentucky, United States, 40536 |
Principal Investigator: | Andrew C. Bernard, M.D. | University of Kentucky |
Responsible Party: | University of Kentucky Medical Center ( Andrew Bernard, M.D. ) |
Study ID Numbers: | 07-0775-P6H |
Study First Received: | September 16, 2008 |
Last Updated: | September 16, 2008 |
ClinicalTrials.gov Identifier: | NCT00754273 |
Health Authority: | United States: Institutional Review Board |
Teicoplanin Respiratory Tract Infections Respiratory Tract Diseases Tigecycline |
Lung Diseases Vancomycin Linezolid Pneumonia |